Watch these video interviews on the iPad edition of this issue by OT reporter Peter Goodwin:
Early HER2+ Breast Cancer: No Benefit with Adjuvant Lapatinib
Edith Perez, MD, discusses the surprising results of the Phase III ALTTO/BIG 2-06 study showing that women with HER2-positive early breast cancer did not benefit from having a second anti-HER2 agent-lapatinib-added to their standard trastuzumab therapy after surgery (Abstract #LBA4, OT 7/10 issue).
Ovarian Cancer: Olaparib+Cediranib Doubles Progression-Free Survival in Patients with High-Grade Serous and BRCA-related Disease
Joyce Liu, MD, MPH, elaborates on her Phase II study showing that women with recurrent high-grade serous or BRCA-dependent ovarian cancer responded well to a combination of the anti-angiogenic agent cediranib and the PARP-inhibitor olaparib, both oral agents (Abstract LBA5500, OT 7/10/14 issue).
NSCLC: Antiangiogenic Ramucirumab Extends Survival in Patients with Relapsed Disease
Maurice Perol, MD, discusses the Phase III, multinational REVEL study showing a survival increase, although modest, with use of ramucirumab for patients with relapsed non-small-cell lung cancer, both squamous and nonsquamous (Abstract #LBA8006, OT 7/25/14 issue).
ER+ Breast Cancer: Exemestane with Ovarian Suppression Extends DFS in Premenopausal Patients
Olivia Pagani, MD, elaborates on the results of a combined analysis of the TEXT and SOFT Phase III trials of premenopausal patients with hormone-responsive breast cancer, showing that they had longer freedom from disease after surgery when treated with exemestane and ovarian suppression rather than tamoxifen (Abstract LBA1, OT 7/25 issue).
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.